SIK family kinase 3Genealiases: L19 · QSK · SEMDK · SIK-3
Q-omics provides the consensus-scored SIK3 profile across patient tissues and cancer cell-line models. SIK3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SIK3 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SIK3 RNA expression shows 20,773 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where SIK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIK3 survival associations across molecular data types. SIK3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIK3 RNA expression–survival associations across cancer types. High SIK3 expression shows unfavorable associations in UVM and BLCA, but favorable associations in KIRC, SKCM, HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SIK3 RNA expression.
This table summarizes SIK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SIK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIK3 shows lower tumor expression in COAD, THCA, KIRP, KIRC and BRCA and higher tumor expression in HNSC. The HNSC box plot shows higher SIK3 RNA expression in tumor versus normal tissue (log2 FC = +0.436, t-test p < 0.001).
This table shows molecular features associated with SIK3 in patient tissues and cancer cell lines. In patient samples, SIK3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SIK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
